Slide 1: May 2025 Investor Presentation
May 2025 Investor Presentation
Slide 2: Disclaimer & Cautionary Statements
Disclaimer & Cautionary Statements This presentation and our earnings call includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materiall
Slide 3: A Pioneer and Leader Focused on Helping Humans Heal
A Pioneer and Leader Focused on Helping Humans Heal Investor Presentation – May 2025 3 Over a decade of experience helping clinicians manage chronic and other hard-to-heal wounds Leading the industry with innovative products and robust supporting clinical data Poised to capitalize on favorable marke
Slide 4: The Most Comprehensive End-to-End Product Ecosystem
The Most Comprehensive End-to-End Product Ecosystem 4Investor Presentation – May 2025 The most studied portfolio of placental products with 50+ clinical & scientific publications and over 300 million payer covered lives. New product innovations leading to untapped opportunities for growth, including
Slide 5: Expansive Donor Network & IP Power
Expansive Donor Network & IP Power Our Product Offering 5Investor Presentation – May 2025 National Network of Birthing Center Partners Ample Placental Supply and Manufacturing Capabilities to Support Continued Growth and Industry Demand Expectant Mothers Introduced to Donation Program Consent for Do
Slide 6: Commercial Scale, Leverage & Extensive Reach
Commercial Scale, Leverage & Extensive Reach 6Investor Presentation – May 2025 Over 75 agencies with 200+ agents nationwide Robust corporate support network Over 200 direct sales professionals nationwide 200+ Extensive commercial coverage with over 300 million payer lives covered Experience selling
Slide 7: Addressing a Large and Unmet Need for Healing Solutions
Addressing a Large and Unmet Need for Healing Solutions Investor Presentation – May 2025 7 Favorable Demographic Trends Increasing Clinical Evidence Expanding Potential For Products 1) Sen CK. Human Wound and Its Burden: Updated 2022 Compendium of Estimates. Adv Wound Care (New Rochelle). 2023;12(12
Slide 8: The Patient Journey in Wound Care
The Patient Journey in Wound Care 8Investor Presentation – May 2025 Private Office Home Health Mobile Health Nursing Facility Assisted Living Facility Wound Care Clinic Hospital Outpatient Hospital Inpatient …and other care settings Mohs surgery Burn/Trauma DFU VLU Limb Salvage Dehiscence Acute Woun
Slide 9: Highlights from Our Expanding Product Portfolio
Highlights from Our Expanding Product Portfolio 9Investor Presentation – May 2025 Flagship Wound Allograft Growing Surgical Offering Expanding into Xenografts
Slide 10: Large Wound Care Business with Growing Surgical Footprint
Large Wound Care Business with Growing Surgical Footprint 10Investor Presentation – May 2025 $0 $50,000 $100,000 $150,000 $200,000 $250,000 $0 00 s LTM Surgical Performance LTM @ Q1:24 LTM @ Q1:25 $0 $50,000 $100,000 $150,000 $200,000 $250,000 $0 00 s LTM Wound Performance LTM @ Q1:24 LTM @ Q1:25 65
Slide 11: Building Library of Evidence for Surgical Applications
Building Library of Evidence for Surgical Applications 11Investor Presentation – May 2025 Recent Publications Showcase Breadth of Potential Use Cases for MIMEDX Products in Surgery Neuro Orthopedic Gastrointestinal Mohs Plastic OB/GYN Foot & Ankle Vascular Transplant Cranioplasty Procedures with AMN
Slide 12: Studies in Process Focused on Significant Surgical Opportunities
Studies in Process Focused on Significant Surgical Opportunities 12Investor Presentation – May 2025 EPIFIX used in Mohs procedures associated with avoidance of postoperative complications and ancillary procedures, compared to patients treated with standard of care. Accepted for Publication Seeking t
Slide 13: Strategic Priorities Position Us to Win in 2025 & Beyond
Strategic Priorities Position Us to Win in 2025 & Beyond Investor Presentation – May 2025 13 Innovate & Diversify Product Portfolio to Maximize Growth Develop & Deploy Programs to Expand Surgical Footprint Enhance Customer Intimacy Leveraging our ability to develop and launch products that meet cust
Slide 14: Adapting to Another Last-Minute Delay to Medicare Reform
Adapting to Another Last-Minute Delay to Medicare Reform Investor Presentation – May 2025 14 LCDs universally proposed by all MACs were delayed until January 1, 2026, and appear unlikely to be a final solution CMS is aware of its ballooning spend in the category and could take action through modific
Slide 15: Financial Highlights
Financial Highlights 15Investor Presentation – May 2025 LTM Net Sales $352MM +5% year-over-year LTM GAAP Gross Margin 82% LTM Adjusted EBITDA1 $75MM 21% of net sales LTM GAAP Net Income $40MM Net Cash Balance $88MM +$59MM vs. Q1:24 LTM Free Cash Flow $65MM Strong & improving financial profile & bala
Slide 16: Experienced, Skillful Leadership Team Executing Strategy
Experienced, Skillful Leadership Team Executing Strategy Investor Presentation – May 2025 Prior Roles Include: Management Team with Track Record of Success in MedTech Joe Capper Chief Executive Officer Doug Rice Chief Financial Officer Butch Hulse Chief Administrative Officer & General Counsel Kim M
Slide 17: Conclusion
Conclusion Investor Presentation – May 2025 17 1 2 3 4 Large & expanding addressable markets Maturing reimbursement & regulatory landscape 5 Competitive advantage with defensible IP and proprietary technology Strong & improving financial profile & balance sheet Experienced & skillful leadership team
Slide 18: Appendix
MIMEDX Appendix 18
Slide 19: Reconciliation of Non-GAAP Measures
Reconciliation of Non-GAAP Measures In addition to our GAAP results, we provide certain non-GAAP measures including Adjusted EBITDA, related margins, Free Cash Flow, Adjusted Gross Profit, Adjusted Gross Margin and Adjusted Net Income. • Adjusted EBITDA consists of GAAP net income excluding: (i) dep
Slide 20: Reconciliation of Non-GAAP Measures (cont.)
Reconciliation of Non-GAAP Measures (cont.) • Each of the adjustments to reconcile Adjusted Net Income to GAAP net income affect individual financial statement captions which are reflected in our consolidated statements of operations, including gross profit. Adjusted Gross Profit is therefore define
Slide 21: Adjusted Gross Profit & Adjusted Gross Profit Margin
Adjusted Gross Profit & Adjusted Gross Profit Margin 21Investor Presentation – May 2025 Three Months Ended Amounts (in millions) March 31, 2025 March 31, 2024 GAAP gross profit $ 71.6 $ 71.7 Amortization of acquisition-related intangible assets 2.5 — Adjusted Gross Profit $ 74.2 $ 71.7 Adjusted Gros
Slide 22: Adjusted EBITDA - QTD
Adjusted EBITDA - QTD 22Investor Presentation – May 2025 Amounts (in millions) for the three months ended March 31, 2025 March 31, 2024 Net income $ 7.0 $ 9.3 Depreciation expense 0.6 0.6 Amortization of intangible assets 2.6 0.2 Interest (income) expense, net (0.5) 1.7 Income tax provision 1.6 2.3
Slide 23: Adjusted Net Income and Adjusted EPS - QTD
Adjusted Net Income and Adjusted EPS - QTD 23Investor Presentation – May 2025 Amounts (in millions) for the three months ended March 31, 2025 March 31, 2024 Net income - GAAP $ 7.0 $ 9.1 Amortization of acquisition-related intangible assets 2.5 — Loss on extinguishment of debt — 1.4 Strategic legal